Setbacks

Ardelyx scraps PhIII drug after researchers raise a safety issue for hyperkalemia patients

The roller coaster ride at Ardelyx is continuing today with news that one of their late-stage assets is being scrapped.

With their lead drug tenapanor being slowly guided to regulators and a hoped-for market showdown for irritable bowel syndrome, Ardelyx $ARDX reported that it has decided to scuttle its Phase III program for RDX7675 in patients with hyperkalemia after tracking a safety issue — drug-related reduction in serum bicarbonate, which can trigger a decision to stop treatment — which essentially blew up its plans to market this treatment for chronic cases.

The setback, though, didn’t seem to faze investors. Ardelyx shares, which have followed a neck-snapping pace of ups and downs, are up a bit this morning. And Leerink’s Seamus Fernandez tells us why:

“(O)ur recent initiation and enthusiasm for ARDX is geared almost entirely toward the oppt’y for tenapanor in hyperphosphatemia. Mgmt expects the termination of ‘7675 to result in cash savings of ~$40M and believes the company now has cash runway into 2019.”

Mike Raab

“The goal for RDX7675 was to develop a palatable product that could be taken chronically to address an important medical need for patients with hyperkalemia (high blood levels of potassium). We are pleased by the activity observed; however, the unanticipated bicarbonate side effect creates a barrier for RDX7675, which we believe could limit its chronic use,” said Mike Raab, chief executive officer of Fremont, CA-based Ardelyx, in a statement.

The biotech has plenty left to do. There’s an early-stage therapy for hyperkalemia called RDX013 that will be moved up. And the next Phase III program for tenapanor for hyperphosphatemia in end-stage renal disease patients on dialysis is being enrolled, with a control arm being added after regulators told them they needed more safety data. An application for tenapanor as a new treatment for IBS-C is also in the works.

When Ardelyx execs rolled out their first round of Phase III data on their IBS drug tenapanor, they were confident that they were playing a winning hand, with statistically significant results in beating out a placebo for easing abdominal pain and increasing bowel movements.

Instead they were crushed after some analysts could barely stifle a yawn over perfectly approvable data that didn’t measure up so well against new data from a rival drug from Synergy $SGYP called Trulance as well as Ironwood’s franchise $IRWD drug Linzess. Then, a few weeks ago, the stock rocketed up on better comparison data.

There’s never a dull moment at Ardelyx.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Chief Medical Officer
Skyhawk Therapeutics Waltham, MA
Chief of Staff, North America
Ipsen Biopharmaceuticals Cambridge, MA
Senior Director, NA Digital Customer Interaction
Ipsen Biopharmaceuticals Cambridge, MA
Manufacturing Associate – Upstream
Molecular Templates Austin, TX
Scientist, Process Development
Molecular Templates Austin, TX
GMP Supervisor - Downstream
Molecular Templates Austin, TX
Quality Control (QC) Associate
Molecular Templates Austin, TX

Visit Endpoints Careers ->